(Il Sole 24 Ore Radiocor) - Milano, 23 apr - The Italian pharmaceuticals and biotech company Chiesi said it reported revenue of 3.625 billion euros in 2025, up by 8.2% at constant foreign exchange rates compared to the year earlier.

EBITDA rose by 25.7% to 931 million euros.

Chiesi highlighted the performance of its Global Rare Diseases business unit, for which sales rose by 22.3% at constant exchange rates to reach 906 million euros, accounting for 50% of the group's overall growth in the US, Europe and international markets.

Chiesi announced that its CEO Giuseppe Accogli will leave the group on May 15. Chief financial officer Jean-Marc Bellemin will maintain his position as CFO but also take on the CEO role on an interim basis. Chiesi noted that the search for a.

new CEO is already underway.

(RADIOCOR) 23-04-26 13:01:01 (0408) 5 NNNN